IN2014KN00948A - - Google Patents

Info

Publication number
IN2014KN00948A
IN2014KN00948A IN948KON2014A IN2014KN00948A IN 2014KN00948 A IN2014KN00948 A IN 2014KN00948A IN 948KON2014 A IN948KON2014 A IN 948KON2014A IN 2014KN00948 A IN2014KN00948 A IN 2014KN00948A
Authority
IN
India
Prior art keywords
same
tautomer
diastereomer
enantiomer
solvate
Prior art date
Application number
Inventor
Grayson B Lipford
Charles M Zepp
Original Assignee
Janus Biotherapeutics Inc
Grayson B Lipford
Charles M Zepp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janus Biotherapeutics Inc, Grayson B Lipford, Charles M Zepp filed Critical Janus Biotherapeutics Inc
Publication of IN2014KN00948A publication Critical patent/IN2014KN00948A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to a compound of Formula (I): or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.
IN948KON2014 2011-10-04 2012-10-03 IN2014KN00948A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161543082P 2011-10-04 2011-10-04
PCT/US2012/058566 WO2013052550A2 (en) 2011-10-04 2012-10-03 Novel imidazole quinoline-based immune system modulators

Publications (1)

Publication Number Publication Date
IN2014KN00948A true IN2014KN00948A (en) 2015-08-21

Family

ID=48044383

Family Applications (1)

Application Number Title Priority Date Filing Date
IN948KON2014 IN2014KN00948A (en) 2011-10-04 2012-10-03

Country Status (8)

Country Link
US (1) US9873694B2 (en)
EP (1) EP2763677B1 (en)
JP (1) JP2014528449A (en)
AU (1) AU2012318694B2 (en)
CA (1) CA2850932A1 (en)
IL (1) IL231957A0 (en)
IN (1) IN2014KN00948A (en)
WO (1) WO2013052550A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EA038972B1 (en) 2016-07-30 2021-11-16 Бристол-Маерс Сквибб Компани Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
US10660877B2 (en) 2016-09-09 2020-05-26 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
EP3661926B1 (en) 2017-08-04 2022-02-23 Bristol-Myers Squibb Company Substituted indole compounds useful as inhibitors of tlr7/8/9
JP7266576B2 (en) 2017-08-04 2023-04-28 ブリストル－マイヤーズ スクイブ カンパニー [1,2,4]triazolo[4,3-a]pyridinyl-substituted indole compounds
CN111448190B (en) 2017-11-14 2023-09-26 百时美施贵宝公司 Substituted indole compounds
ES2960411T3 (en) 2017-12-18 2024-03-04 Bristol Myers Squibb Co 4-azaindole compounds
WO2019126113A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Substituted indole compounds useful as tlr inhibitors
SG11202005704RA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co 6-azaindole compounds
CN111511730B (en) 2017-12-19 2023-07-25 百时美施贵宝公司 Amide substituted indole compounds useful as TLR inhibitors
CN111491929B (en) 2017-12-20 2023-11-28 百时美施贵宝公司 Aminoindole compounds useful as TLR inhibitors
WO2019126083A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
CA3085942A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
CN113811299A (en) * 2019-03-15 2021-12-17 博笛生物科技有限公司 Immunomodulatory compositions and methods for treating cancer
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
BR112023021107A2 (en) 2021-04-16 2023-12-12 Gilead Sciences Inc THIENOPIRROL COMPOUNDS
US11939328B2 (en) 2021-10-14 2024-03-26 Incyte Corporation Quinoline compounds as inhibitors of KRAS

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE509102T1 (en) 1994-07-15 2011-05-15 Univ Iowa Res Found IMMUNOMODULATORY OLIGONUCLEOTIDES
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AR006928A1 (en) 1996-05-01 1999-09-29 Pioneer Hi Bred Int AN ISOLATED DNA MOLECULA CODING A GREEN FLUORESCENT PROTEIN AS A TRACEABLE MARKER FOR TRANSFORMATION OF PLANTS, A METHOD FOR THE PRODUCTION OF TRANSGENIC PLANTS, A VECTOR OF EXPRESSION, A TRANSGENIC PLANT AND CELLS OF SUCH PLANTS.
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998050547A2 (en) 1997-05-07 1998-11-12 Schering Corporation Human toll-like receptor proteins, related reagents and methods
ATE370740T1 (en) 1997-05-20 2007-09-15 Ottawa Health Research Inst METHOD FOR PRODUCING NUCLEIC ACID CONSTRUCTS
ES2284247T3 (en) 1998-04-03 2007-11-01 University Of Iowa Research Foundation METHODS AND PRODUCTS TO STIMULATE THE IMMUNITY SYSTEM USING OLIGONUCLEOTIDES AND IMMUNOTHERAPEUTIC CYTOQUINS.
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
JP2000119271A (en) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
CN1346350A (en) 1999-01-22 2002-04-24 依兰制药公司 Compound which inhibiti leukocyte adhesion mediated by VLA-4
IL148844A0 (en) 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
CN1721443A (en) 2000-05-25 2006-01-18 先灵公司 Human receptor proteins, related reagents and methods
BR0211962A (en) 2001-08-17 2005-04-19 Coley Pharm Group Inc Combination of Enhanced Activity Immunostimulatory Oligonucleotide Parts
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
BRPI0411514A (en) * 2003-06-20 2006-08-01 Coley Pharm Gmbh small molecule toll-like receptor antagonists
EP1851218A2 (en) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP5247458B2 (en) * 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
US20100010217A1 (en) * 2006-03-23 2010-01-14 Valiante Nicholas M Methods for the preparation of imidazole-containing compounds
US8027888B2 (en) * 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US7943771B2 (en) * 2007-01-24 2011-05-17 Chemagis Ltd. Imiquimod production process
EP3176169A1 (en) * 2007-01-31 2017-06-07 Chongxi Yu Positively charged water-soluble prodrugs of 1h-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
KR20110095857A (en) 2008-09-10 2011-08-25 칼립시스, 인코포레이티드 Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011068233A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds

Also Published As

Publication number Publication date
US9873694B2 (en) 2018-01-23
WO2013052550A3 (en) 2014-05-15
EP2763677A4 (en) 2015-05-20
EP2763677A2 (en) 2014-08-13
CA2850932A1 (en) 2013-04-11
AU2012318694A1 (en) 2014-05-22
JP2014528449A (en) 2014-10-27
AU2012318694B2 (en) 2016-12-22
WO2013052550A2 (en) 2013-04-11
EP2763677B1 (en) 2020-02-26
IL231957A0 (en) 2014-05-28
US20140242121A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
IN2014KN00948A (en)
PH12020550552A1 (en) Inhibitors of hepatitis c virus
MY165087A (en) Neprilysin inhibitors
MX342212B (en) Substituted aminobutyric derivatives as neprilysin inhibitors.
MY170935A (en) Neprilysin inhibitors
EA026667B9 (en) Pharmaceutical composition for treating hepatitis c virus
MX2013011589A (en) Methods and compositions for treating parkinson's disease.
WO2010108074A3 (en) Inhibitors of pi3 kinase
MX2013006802A (en) Neprilysin inhibitors.
MX2013007336A (en) Bi-heteroaryl compounds as vps34 inhibitors.
MX2013011591A (en) Methods and compositions for treating neurodegenerative diseases.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX350746B (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection.
TN2015000574A1 (en) Compounds and compositions as inhibitors of mek
CA2881554C (en) Methods for inhibiting fascin
MX348393B (en) Polymorph of rifaximin and process for the preparation thereof.
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
PH12017500089B1 (en) Aldosterone synthase inhibitors
MX342153B (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease.
WO2013028615A8 (en) Novel cyclosporin derivatives for the treatment and prevention of viral infections
WO2012164055A3 (en) New compounds, synthesis and use thereof in the treatment of pain
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase
WO2013015657A3 (en) Novel compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same
WO2012008765A3 (en) Pharmaceutical composition for treating or preventing cancer